Geary Richard S's Form 4/A amendment
AmendedIonis Pharmaceuticals Inc (IONS) · filed Nov 7, 2025
- Accession no.
- 0000874015-25-000276
- Filed
- Nov 7, 2025
- Trade date
- Nov 3, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Nov 3, 2025
This filing lists 4 non-derivative transactions and 2 derivative transactions. It carries over 7 transactions from the original filing that it did not restate. Open-market sales total $6.83M. It was filed 4 days after the trade.
This amendment restates part of 0000874015-25-000270 (filed Nov 3, 2025). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Geary Richard SCIK 0001442730 | Officer (EVP, Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 3, 2025 | Common Stock | MOption exerciseAcquired | +775 | $60.89 | +$47,189.75 | 60,432 | Direct | |
| Nov 3, 2025 | Common Stock | SSaleDisposed | −775 | $75.05F2 | −$58,163.75 | 59,657 | Direct | |
| Nov 3, 2025 | Common Stock | MOption exerciseAcquired | +905 | $56.78 | +$51,385.9 | 60,562 | Direct | |
| Nov 3, 2025 | Common Stock | SSaleDisposed | −905 | $75.05F2 | −$67,920.25 | 59,657 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 3, 2025 | Common Stock | MOption exerciseDisposed | −905 | $0.00 | $0 | 15,538 | Direct | |
| Nov 3, 2025 | Common Stock | MOption exerciseDisposed | −775 | $0.00 | $0 | 19,101 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0000874015-25-000270 (filed Nov 3, 2025).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 31, 2025 | Common Stock | MOption exerciseAcquired | +34,585 | $60.89 | +$2,105,880.65 | 114,242 | Direct | |
| Oct 31, 2025 | Common Stock | SSaleDisposed | −34,585 | $75.11F2 | −$2,597,679.35 | 79,657 | Direct | |
| Oct 31, 2025 | Common Stock | MOption exerciseAcquired | +34,664 | $56.78 | +$1,968,221.92 | 114,321 | Direct | |
| Oct 31, 2025 | Common Stock | SSaleDisposed | −34,664 | $75.11F2 | −$2,603,613.04 | 79,657 | Direct | |
| Oct 31, 2025 | Common Stock | SSaleDisposed | −20,000 | $75.11F2 | −$1,502,200 | 59,657 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 31, 2025 | Common Stock | MOption exerciseDisposed | −34,664 | $0.00 | $0 | 16,443 | Direct | |
| Oct 31, 2025 | Common Stock | MOption exerciseDisposed | −34,585 | $0.00 | $0 | 19,876 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.47 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Referenced by the price of 3 transactions in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Referenced by the price of 2 transactions in Table I.